But what about vaccines from Moderna and Novavax? Here's what we know. Australia's medicines watchdog has approved Pfizer's new COVID-19 vaccine and it's set to be available in the coming months.

Besides Sanofi deal for nuvaxovid, Novavax has few opportunities to generate additional revenue, which likely means its stock ...

The market expects Novavax (NVAX) to deliver a year-over-year increase in earnings on lower revenues when it reports results for the quarter ended September 2024. This widely-known consensus ...

Novavax has been gearing up to launch a phase 3 trial of what may result in an important product: A combined flu and coronavirus vaccine. But the company now faces a roadblock, saying regulators ...

Nov 5 (Reuters) - Novavax (NVAX.O), opens new tab said on Tuesday that it has entered into a termination and settlement agreement with the UK Health Security Agency (UKHSA) related to its COVID-19 ...

Novavax ( (NVAX)) has issued an announcement. Novavax, Inc. and the UK Health Security Agency have reached a settlement to terminate their SARS-COV-2 Vaccine Supply Agreement, resolving disputes ...

Novavax ends UK COVID-19 vaccine contract, agreeing to repay $123.8M in quarterly installments by 2027 as part of settlement. Vandana Singh Robinhood, Novavax, Phunware, Lucid Group, And Tesla ...

Novavax (NVAX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.

Novavax Inc.’s stock tumbled 19% early Wednesday after the company said the Food and Drug Administration has placed a clinical hold on its COVID-19-and-flu combination and stand-alone flu ...

Novavax said federal regulators put a clinical hold on its application for a combination Covid-19 and influenza vaccine and stand-alone flu inoculation, sending shares down sharply. The vaccine ...

In early pandemic days, Novavax (NASDAQ: NVAX) shares soared as investors bet on the company's ability to bring a coronavirus vaccine to market. But as the biotech fell behind in the race and ...